Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Nicoletta Ciccarelli, Roberto Cauda, Simona Di Giambenedetto, Annalisa Mondi, Massimiliano Fabbiani, Manuela Colafigli, Alessandro D'Avino, Alberto Borghetti, Roberta Gagliardini, Andrea De Luca, A. De Luca

Risultato della ricerca: Contributo in rivistaArticolo in rivista

31 Citazioni (Scopus)

Abstract

AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.
Lingua originaleEnglish
pagine (da-a)1843-1849
Numero di pagine7
RivistaJournal of Antimicrobial Chemotherapy
Volume70
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • antiviral
  • combined antiretroviral therapy
  • dual therapy

Fingerprint Entra nei temi di ricerca di 'Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study'. Insieme formano una fingerprint unica.

Cita questo